Adaptation of global hemostasis to therapeutic hypothermia in patients with out-of-hospital cardiac arrest: Thromboelastography study by Trąbka-Zawicki, Aleksander et al.
Address for correspondence: Aleksander Trąbka-Zawicki, MD, Department of Interventional Cardiology, Jagiellonian  
University, John Paul II Hospital, ul. Prądnicka 80, 31–202 Kraków, Poland, tel: +48 12 614 35 01, fax: +48 12 614 30 47, 
e-mail: atz84@o2.pl
Received: 6.12.2016 Accepted: 21.05.2017
Adaptation of global hemostasis to therapeutic  
hypothermia in patients with out-of-hospital  
cardiac arrest: Thromboelastography study
Aleksander Trąbka-Zawicki1, Marek Tomala1, Aleksander Zeliaś1,  
Elżbieta Paszek1, Wojciech Zajdel1, Ewa Stępień2, Krzysztof Żmudka1
1Department of Interventional Cardiology, Jagiellonian University, John Paul II Hospital, Krakow, Poland 
2Department of Medical Physics, Marian Smoluchowski Institute of Physiscs, Faculty of Physics,  
Astronomy, and Applied Computer, Jagiellonian University, Krakow, Poland 
Abstract
Background: The use of mild therapeutic hypothermia (MTH) in patients after out-of-hospital cardiac 
arrest (OHCA) who are undergoing primary percutaneous coronary intervention (pPCI) can protect 
patients from thromboembolic complications. The aim of the study was to evaluate the adaptive mecha-
nisms of the coagulation system in MTH-treated comatose OHCA survivors. 
Methods: Twenty one comatose OHCA survivors with acute coronary syndrome undergoing imme-
diate pPCI were treated with MTH. Quantitative and qualitative analyses of physical clot properties 
were performed using thromboelastography (TEG). Two analysis time points were proposed: 1) during 
MTH with in vitro rewarming conditions (37°C) and 2) after restoration of normothermia (NT) under 
normal (37°C) and in vitro cooling conditions (32°C). 
Results: During MTH compared to NT, reaction time (R) was lengthened, clot kinetic parameter (a) 
was significantly reduced, but no effect on clot strength (MA) was observed. Finally, the coagulation 
index (CI) was significantly reduced with clot fibrinolysis attenuated during MTH. The clot lysis time 
(CLT) was shortened, and clot stability (LY60) was lower compared with those values during NT. In vitro 
cooling generally influenced clot kinetics and reduced clot stability after treatment. 
Conclusions: Thromboelastography is a useful method for evaluation of coagulation system dysfunc-
tion in OHCA survivors undergoing MTH. Coagulation impairment in hypothermia was associated 
with a reduced rate of clot formation, increased weakness of clot strength, and disturbances of fibrinoly-
sis. Blood sample analyses performed at 32°C during MTH, instead of the standard 37°C, seems to 
enhance the accuracy of the evaluation of coagulation impairment in hypothermia. (Cardiol J 2019; 26, 
1: 77–86)
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Introduction
Despite the fact that 60% of out-of-hospital 
cardiac arrests (OHCA) survivors are treated by 
emergency medical service personnel, their prog-
nosis is still very poor with survival rates reaching 
only 9.5% (8.8–10.2%) [1–5]. Two independent, 
randomized control trials for myocardial infarction 
patients who had OHCA confirmed an improvement 
in survival and neurological outcomes resulting 
from the application of mild therapeutic hypother-
mia (MTH) [6, 7]. The postulated mechanism of 
MTH action occurs via a decrease in cerebral oxy-
gen demand, which reduces excitatory amino acid 
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release and improves brain glucose utilization [8, 9]. 
There are limited data in the literature regarding 
hypothermia effects on coagulation. Proper evalua-
tion of the coagulation system during hypothermia 
in patients with acute coronary syndrome (ACS) 
complicated by cardiac arrest will avoid bleed-
ing and thrombotic complications. However, it is 
known that MTH interacts with the coagulation 
system mainly through change of platelets shape, 
impairment of its function and shortening of its 
life span, emphasizing its influence on the ability 
of platelets to respond to activating stimuli, as well 
the role of shear-induced platelet aggregation by 
increasing blood viscosity. Expression of von Ville-
brand factor (vWF) in endothelial cells is higher, 
and retention on the cell surface is prolonged, as 
well recognition of vWF with factor VIII is reduced 
at low temperatures [10]. 
As a result of cardiac arrest (CA), complex 
processes such as systemic ischemia/reperfusion 
responses, brain injury, and acidosis come into 
play [11]. MTH by lowering the cardiac output 
that modulates the level of plasma cytokines and 
increasing the level of endotoxins involved in 
systemic inflammation has an indirect effect on 
coagulation abnormalities [12–14].
Thromboelastography (TEG), is routinely per-
formed at 37°C, however some authors have sug-
gested that this approach may not reflect the real 
hemostatic function in hypothermic patients [15].
Some studies suggest that hypothermia may 
modify the coagulation cascade due to regulation 
of coagulation factor activities; most of which are 
thermo-sensitive [16, 17]. In practice, this anti-
coagulation effect may have an additional cardio-
protective action, especially for CA patients who 
usually have an imbalanced coagulation cascade 
toward thrombosis [1, 2, 18]. In these patients 
a strict control of the coagulation system is crucial 
for proper treatment and prevention of undesir-
able effects. It should be noted that the previously 
published results were obtained by both TEG and 
throboelastometry methods at 37°C in vitro; no 
clinical data regarding MTH patients performed 
under cooling in vitro conditions are available [19]. 
There are a few studies investigating hypothermic 
effects on coagulation in OHCA patients, some of 
these have indicated a prolonged clot initiation 
during hypothermia and others contradicted this 
finding [20, 21]. Moreover, there are a lack of stud-
ies conducted under conditions that reflect the in 
vivo hypothermia environment, and those that are 
available were performed on healthy volunteers 
in model conditions [16, 17]. In the current study, 
the impact was evaluated of hypothermia on the 
coagulation system’s adaptive mechanisms under 
normo- and hypothermic conditions in vivo and in 
vitro of comatose OHCA survivors.
Methods
Study design
This prospective study was conducted as 
a single-center evaluation study. The protocol was 
approved by the Jagiellonian University Ethics 
Committee in Krakow. Patients were consecutively 
recruited between January 2014 and September 
2015 to the cardiac intensive care unit of the Depart-
ment of Interventional Cardiology at John Paul II 
Hospital in Krakow, Poland. Written informed 
consent was obtained from patients regaining con-
sciousness after cardiac arrest. MTH was achieved 
with the use of an endovascular cooling device 
(Zoll Medical Corporation Chelmsford, MA) which 
was set to a target temperature of 32.0°C and was 
maintained for 24 h. Subsequently, rewarming was 
performed at a rate of 0.2°C/h. Inclusion criteria 
required ACS complicated by OHCA with return 
of spontaneous circulation. Patients had to be 
> 18 years of age and undergo primary percutane-
ous coronary intervention (pPCI) to a culprit artery 
with implantation of a coronary stent. Because 
patients with ST-segment elevation myocardial 
infarction (STEMI) were admitted directly to the 
catheterization laboratory without additional diag-
nostic tests, we compared a group with STEMI vs. 
a non-ST-segment elevation myocardial infarction 
(NSTEMI) group. Patients were excluded if they 
had recognized coagulopathy or they had been 
treated with MTH before hospital admission. 
Quantitative and qualitative measurements of 
clot physical properties were assessed using TEG 
(Haemoscope Corp., Niles, Illinois, USA) [22, 23]. 
At discharge, neurological outcomes were assessed 
according to the Pittsburgh Cerebral Performance 
Category (CPC) [24]. CPC scores of 1 and 2 were 
defined as good neurological outcomes, whereas 
CPC scores of 3, 4, and 5 showed an unfavorable 
neurological outcome.
Patient management
During the procedure, each patient received 
unfractionated, intravenous (i.v.) heparin, (accord-
ing to their weight) and a dual antiplatelet drugs 
via a nasogastric tube. A loading dose of 180 mg 
ticagrelor and 300 mg acetylsalicylic acid (ASA) 
was administered upon admission, followed by 
ticagrelor 90 mg twice daily and 75 mg ASA once 
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daily. During the procedure, glycoprotein (GP) 
IIb/IIIa receptor inhibitor was administered at the 
discretion of the interventional cardiologist. After 
the intervention, patients were hospitalized in the 
Cardiology Intensive Care Unit and received stand-
ard treatment. The pharmacological treatment 
summary during the study is presented in Table 1. 
Blood sampling
Whole blood for hematology and coagulation 
analyses was collected at admission prior to per-
forming pPCI (basal, an average body temperature 
of 35.3 ± 0.6°C), 22 ± 4 h after induction of hy-
pothermia (MTH, at an average core temperature 
of 32.2 ± 0.1°C) and 21 ± 9 h after patients were 
rewarmed to normothermia (NT, at an average 
core temperature of 36.7 ± 0.2°C). The second 
set of samples was drawn for biochemical analysis. 
For TEG, blood was collected from the femoral 
vein into tubes containing 2.8 mL of citrate. Sub-
sequently, 1 mL of venous blood was transferred 
into a vial containing kaolin and mixed by slow 
inversion. Then, 320 µL of blood was immediately 
transferred into two heparinized caps with 20 µL of 
0.2M CaCl2 and analyzed by TEG simultaneously 
at in vitro temperatures of 37°C and 32°C. 
TEG analysis
Using the TEG analyzer, key parameters were 
determined under two temperature conditions 
(37°C and 32°C; Table 2). There were two key 
TEG parameters reflecting the function of plasma 
coagulation: R — time from the start of a sample 
run until the first significant level of detectable 
clot formation, which resulted from cleavage of 
fibrinogen by thrombin; a — rate of thrombin burst 
and fibrin formation and cross-linking. Platelets and 
fibrinogen activity are represented by MA, a meas-
ure of the dynamic properties of fibrin and platelets 
by binding to GP IIb/IIIa receptor. Together with 
Table 1. Summary of the drug use in study intervals.
Parameters Basal (n = 21) MTH (n = 20) NT (n = 19)
UFH (ptn) 4 (19%) 0 (0%) 0 (0%)
LMWH(ptn) 1 (5%) 2 (10%) 1 (5%)
ASA(ptn) 8 (38%) 20 (100%)* 17 (90%)^
P2Y12 (ptn) 2 (10%) 20 (100%)* 19 (100%)^
Clopidogrel (ptn) 2 (10%) 0 (0%) 0 (0%)
Ticagrelor (ptn) 0 (0%) 20 (100%) 19 (100%)^
*p < 0.05 (MTH vs. Basal); ^p < 0.05 (NT vs. Basal)
ASA — acetylsalicylic acid; LMVH — low molecular weight heparin; MTH — mild therapeutic hypothermia; NT — normothermia; P2Y12 —  
inhibitor P2Y12; UFH — unfractionated heparin; ptn — patients
(1) All patients in hypothermia received dual antiplatelet therapy (ASAMTH = 100% vs. ASABasal = 38%; p < 0.05) and (P2Y12MTH = 100% vs.  
P2Y12Basal = 10%; p < 0.05).
(2) In 2 normothermic patients, ASA was discontinued due to bleeding from the respiratory tract and suspicion of central nervous system 
bleeding. 
(3) All patients in normothermia received P2Y12. 
Table 2. Summary of basic parameters of thromboelastography (TEG).
Reaction time R The latency period from the time that blood was placed in the TEG analyzer until  
initial fibrin formation. Represents enzymatic reaction
Clot kinetics K A measure of the speed to reach 20 mm amplitude. Represents clot kinetics
a A measure of fibrin build-up rapidity and cross-linking (clot-strengthening) by factor XIII; 
it also depended on platelet participation in clot formation and the concentration  
of fibrinogen and fibrin polymerization ability. Represents fibrinogen level
Clot strength MA A direct function of maximum dynamic properties of fibrin and platelet bonding  
via glycoprotein IIb/IIIa. Represents maximum platelet function.
Coagulation index CI A linear combination of R, K, alpha, MA
Clot stability LY60 A measure of the rate of amplitude reduction 60 min after MA.  
Estimates %lysis based on amplitude reduction after MA 
Clot lysis time CLT The elapsed time between MA and 2 mm amplitude or less post MA
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the K parameter, MA demonstrates the strength 
of fibrin clot. The K kinetics achieve a certain clot 
firmness. Fibrinolysis properties are documented 
by LY60, and CLT. Coagulation index (CI) defines 
global clotting.
With regard to standard coagulation tests, the 
international normalized ratio, activated partial 
thromboplastin time, thrombin time, and fibrino-
gen concentrations were analyzed employing the 
BCS XP System (Siemens, Healthcare, Poland). 
The complete blood count test was done by the 
Sysmex XN1000 haematology analyzer (Sysmex 
Corporation, Japan). 
Statistical analysis
Statistical analyses were performed using 
Statistica 10.0 package. Distribution of variables 
was tested by Kolmogorov-Smirnov normality test. 
Quantitative variables were characterized using 
descriptive statistics. Analyzing the relationships 
of qualitative data was done with Pearson’s c2 test 
and Fisher’s exact, two-sided test. Continuous 
variables were reported as mean ± standard devia-
tion (SD) or medians and interquartile ranges as 
appropriate. Student t-test or Mann Whitney test 
was used to determine significance between the 
variables R, K, a, MA, TMA, LY60, and CI levels 
in each group. A p-value £ 0.05 was considered 
statistically significant.
Results
Clinical characteristics
In a cohort of 21 consecutive OHCA patients 
(67 ± 11 years) 3 deaths occurred: 2 patients 
during assessment and 1 after collecting the final 
samples. Baseline demographic and resuscitation 
characteristics of those with and without STEMI 
undergoing coronary angiography are shown in 
Table 3.
Laboratory investigations
Standard laboratory values measured at 37°C 
during admission (basal), MTH and normothermia 
after rewarming (NT) are shown in Table 4. 
Variables
Variable R. Under in vivo conditions, the 
value of R during MTH (32.2 ± 0.1°C) was 9.9 ± 
± 2.0 min and did not differ significantly compared 
to the R during NT (36.7 ± 0.2°C), which was 
9.1 ± 2.4 min. In vitro, there was no significant 
difference between the values of RMTH37°C vs. RMTH32°C 
and RNT37°C vs. RNT32°C (Table 5).
Variable a. Under in vivo conditions, dur-
ing MTH, a was 54 ± 8°. This value indicated 
a significant impairment of fibrin build-up compared 
to NT after rewarming, in which a was 65 ± 7°; 
p < 0.05 (Table 6). The sample examination at 
different temperatures in vitro demonstrated 
significant differences in the values of aMTH37°C vs. 
aMTH32°C and a NT37°C vs. aNT32°C (Table 5). 
Variable K. During MTH, a significant in-
crease of clot kinetic properties (K) in comparison 
to NT conditions was observed: 2.8 ± 1.1 vs. 
2.0 ± 0.7 min; p < 0.05 (Table 6). The sample 
examination at different temperatures in vitro 
demonstrated no differences in KMTH37°C vs. KMTH32°C 
and KNT37°C vs. KNT32°C (Table 5).
Variable MA. Under in vivo conditions, dur-
ing MTH, there was no change in MA. In the NT, 
a significant increase in clot strength from MAMTH 
63 ± 7 to MANT 69 ± 6 mm, p < 0.05 was observed. 
Under in vitro conditions, no significant differences 
in MAMTH37°C vs. MAMTH32°C and MANT37°C vs. MANT32°C 
were observed (Table 5).
Variable CI. In the NT a significant increase 
in CI from CIMTH –3.5 ± 2.4 to CINT –1.1 ± 2.8/s was 
observed. Under in vitro conditions, no significant 
differences in the parameter CIMTH37°C vs. CIMTH32°C 
and CINT37°C vs. CINT32°C were observed (Table 5).
Variable LY60. In vivo conditions, during 
MTH, a significant reduction the clot stabiliza-
tion from LY60MTH 1.4 ± 1.4% to LY
60
NT 3.7 ± 2.3% 
(p < 0.05) was observed. In vitro, a significant dif-
ference in the parameter LY60 between the inter-
vals: LY60MTH37°C vs. LY
60
MTH32°C; LY
60
NT37°C vs. LY
60
NT32°C 
was observed (Table 5).
The parameter CLT
There were no significant differences in CLT 
both under in vivo and in vitro conditions, during 
MTH and NT (Table 5). 
Discussion
Major findings of the study were: coagulation 
impairment during hypothermia manifested by 
a reduced rate of clot formation, increased weakness 
of clot strength, and disturbances of fibrinolysis 
with reduced fibrinogen levels. Based on previous 
studies, the impairment of the coagulation system 
after application of MTH to OCHA patients should 
be considered as an effect of reduced temperature 
and ischemic-reperfusion damage resulting from 
CA. Changes include inhibition of enzyme func-
tion (zymogens) and abnormal platelet function as 
well as increased fibrinolysis or a combination of 
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Table 3. Baseline characteristics of patients after out-of-hospital cardiac arrest due to acute myocardial 
infarction undergoing mild therapeutic hypothermia.
STEMI (n = 11) NSTEMI (n = 10) P
Demographic data
Males 9 (82%) 8 (80%) 0.9
Age 65 ± 9 68 ± 13 0.5
History of myocardial infarction 0 1 (10%) 0.3
History of ischemic heart disease 1 (9%) 2 (20%) 0.5
Arterial hypertension 7 (64%) 7 (70%) 0.8
Diabetes mellitus type 2 2 (18%) 4 (40%) 0.3
Dyslipidemia 4 (36%) 5 (50%) 0.5
Obesity 4 (36%) 4 (40%) 0.9
Tobacco smoking 4 (36%) 2 (20%) 0.4
Revascularization 0 2 (20%) 0.1
Chronic kidney disease stage 5 0 1 (10%) 0.5
Atrial fibrillation 0 2 (20%) 0.1
Arrest data
Initial cardiac arrest rhythm:
VF/VT 10 (91%) 7 (70%) 0.2
Asystole 0 2 (20%) 0.1
Pulseless electrical activity 1 (9%) 1 (10%) 0.9
Time to ROSC [min] 27 ± 15 19 ± 16 0.2
Witness (yes) 11 (100%) 10 (100%) 1
Bystander CPR (yes) 7 (64%) 7 (70%) 0.8
Hospital patients on admison data
GCS score (3–4) 7 (64%) 6 (60%) 0.9
GCS score (5–6) 4 (36%) 4 (40%) 0.9
Medium HR [bpm] 102 ± 26 98 ± 13 0.7
Medium MAP [mmHg] 94 ± 26 96 ± 23 0.9
Cardiogenic shock (yes) 3 (27%) 1 (10%) 0.3
Time to MTH [min] 117 ± 37 154 ± 66 0.2
STEMI location 
Anterior 5 (45%) NA
Inferior 2 (18%) NA
Lateral 1 (9%) NA
Anterior-lateral 2 (18%) NA
Inferior-lateral 1 (9%) NA
LBBB 0 2 (20%) 0.1
RBBB 2 (18%) 2 (20%) 0.9
Coronary angiographic
Culprit leasion:
Left main artery 0 (0%) 0 (0%) –
Left anterior descending artery 6 (55%) 2 (20%) 0.1
Diagonal artery 0 (0%) 1 (10%) 0.3
Intermediate artery 1 (9%) 0 (0%) 0.3
Left circumfex artery 1 (9%) 2 (20%) 0.5
Marginal artery 2 (18%) 2 (20%) 0.9
Right coronary artery 1 (9%) 2 (20%) 0.5
MVD (more than 1-VD) 0 (%) 1 (10%) 0.3
Culprit occlusions 8 (73%) 4 (40%) 0.1
Æ
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Table 3 (cont). Baseline characteristics of patients after out-of-hospital cardiac arrest due to acute my-
ocardial infarction undergoing mild therapeutic hypothermia.
STEMI (n = 11) NSTEMI (n = 10) P
Intervention findings
PCI 10 (91%) 10 (100%) 0.3
PCI type:
Bare metal stent 1 (9%) 0 (0%) 0.3
Drug eluting stent 9 (82%) 10 (100%) 0.2
Used of GP IIb/IIIa inhibitors 1 (9%) 0 (0%) 0.3
Time from cardiac arrest to door to balloon [min] 107 ± 33 155 ± 68 0.06
Time PCI [min] 29 ± 18 18 ± 9 0.1
Hospital patients at discharge
Echocardiogram:
Normal (EF > 50%) 6 (55%) 4 (40%) 0.5
Mild-moderate (EF 30–49%) 3 (27%) 6 (60%) 0.1
Severe (EF < 30%) 2 (18%) 0 (0%) 0.2
Medication
ASA 10 (91%) 8 (80%) 0.5
Clopidogrel 0 (0%) 1 (10%) 0.3
Ticagrelor 11 (100%) 9 (90%) 0.3
LMWH 3 (27%) 6 (60%) 0.1
Statin 4 (36%) 7 (70%) 0.1
ACEI 6 (54%) 5 (50%) 0.8
Digoxin 0 (0%) 1 (10%) 0.3
Beta-blocker 6 (54%) 4 (40%) 0.5
Diuretic 8 (72%) 5 (50%) 0.3
Cordarone 1 (9%) 1 (10%) 0.9
Clinical characteristics
Cerebral edema 1 (9%) 3 (30%) 0.2
Stroke 0 (0%) 2 (20%) 0.1
Stent thrombosis 0 (0%) 0 (0%) –
Pneumonia 6 (55%) 6 (60%) 0.8
Bleeding 2 (18%) 5 (50%) 0.1
Cardiogenic shock (yes) 5 (45%) 4 (40%) 0.8
Re-cardiac arrest 3 (27%) 2 (20%) 0.7
Neurological outcome
Good neurological outcome 7 (64%) 5 (50%) 0.5
Death 2 (18%) 1 (10%) 0.6
ACEI — angiotensin-converting-enzyme inhibitor; ASA — acetylsalicylic acid; CPR — cardiopulmonary resuscitation; EF — ejection fraction; 
GCS — Glasgow Coma Scale; GP — glycoprotein; HR — heart rate; LBBB — left bundle branch block; LMWH — low molecular weight heparin; 
MAP — mean arterial pressure; MTH — mild therapeutic hypothermia; MVD — multivessel disease; NSTEMI — non-ST-segment elevation 
myocardial infarction; PCI — percutaneous coronary intervention; RBBB — right bundle branch block; ROSC — return of spontaneous  
circulation; STEMI — ST-segment elevation myocardial infarction; VT/VF — ventricular tachycardia/ventricular fibrillation
Due to STEMI, patients were admitted directly to a catheterization laboratory (without additional diagnostic tests), and STEMI vs. NSTEMI 
groups were compared. No significant differences between groups were observed: (1) the main mechanism of cardiac arrest was ventricular 
fibrillation; (2) Arterial hypertension was the most commonly occurring risk factor for atherosclerosis in both groups; (3) Time frame to  
balloon was longer in NSTEMI patients (delay of revascularization resulted from the exclusion of non-cardiogenic reasons of cardiac arrest;  
p = 0.06); (4) In the STEMI group, > 50% left anterior descending artery was due to infarct-related artery; (5) Cardiogenic shock occurred 
at the same frequency in both groups (45% vs. 40%; p = 0.8); (6) The bleeding rates were  greater in NSTEMI (STEMI vs. NSTEMI, 18% vs. 
50%; p = 0.1); and (7) The number of favourable neurological outcomes (as identified by the Pittsburgh Cerebral Performance Category 
scores 1 and 2) were similar in patients in both groups (64% vs. 50%; p = 0.5).
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any of those factors [11, 25, 26]. TEG is a bedside 
test which allows assessment of the interaction 
between coagulation factors, platelets, fibrin and 
fibrinolysis. Routinely, TEG is performed at 37°C, 
nevertheless some studies were dedicated to test 
the influences of temperature on TEG measure-
ments [27, 28]. The results of the current TEG 
analysis under in vivo conditions demonstrated 
that application of MTH impaired both propagation 
of coagulation (a-angle), as well as K and MA, yet 
did not affect the R time. In contrast, a delay in clot 
lysis (reflected by low LY60 and CI) was detected in 
the present study. Some observations are consist-
ent with previous studies in which hemostasis in 
OHCA survivors treated with MTH, using both 
TEG® as well as rotational thromboelastogram 
(ROTEM®) analysis was investigated and the im-
Table 6. A summary of the thromboelastography 
parameters for patients with out-of-hospital  
cardiac arrest undergoing mild therapeutic  
hypothermia (MTH) during and after treatment 
(normothermia [NT])
Parameter MTH NT
R [min] 9.9 ± 2.0 9.1 ± 2.4
a [deg] 54 ± 8 65 ± 7*
K [min] 2.8 ± 1.1 2.0 ± 0.7*
MA [mm] 63 ± 7 69 ± 6*
CI [s–1] –3.5 ± 2.4 –1.1 ± 2.8*
LY60 [%] 1.4 ± 1.4 3.7 ± 2.3*
CLT [min] 479 ± 446 630 ± 502
The data shown are the mean and standard deviation; *p < 0.05 
(NT vs. MTH)
a — angle to define clot kinetics; CI — coagulation index; CLT — 
clot lysis time; LY60 — rate of clot stability after 60 min; K — time to 
reach 20 mm amplitude; MA — maximum amplitude; R — time to 
define clot kinetics. All abbreviations are defined in Table 2.
Table 5. A summary of the thromboelastography 
(TEG) parameters for patients with out-of-hos-
pital cardiac arrest undergoing mild therapeutic 
hypothermia (MTH) during and after treatment 
(normothermia [NT]). TEG was performed at 
32°C and 37°C in vitro conditions.
Parametr MTH P NT P
R37°C (min) 9.3 ± 1.9 > 0.05 9.1 ± 2.4 > 0.05
R32°C (min) 9.9 ± 2.0 9.1 ± 2.2
K37°C (min) 2.5 ± 1.3 > 0.05 2.0 ± 0.7 > 0.05
K32°C (min) 2.8 ± 1.1 2.1 ± 0.6
a37°C (deg) 58 ± 10 < 0.05* 65 ± 7 < 0.05*
a32°C (deg) 54 ± 8 62 ± 6
MA37°C (mm) 62 ± 7 > 0.05 69 ± 6 > 0.05
MA32°C (mm) 63 ± 7 70 ± 5
LY6037°C (%) 2.7 ± 2.2 < 0.05* 3.7 ± 2.3 < 0.05*
LY6032°C (%) 1.4 ± 1.4 2.3 ± 1.9
CI37°C (/s) –2.8 ± 2.8 > 0.05 –1.1 ± 2.8 > 0.05
CI32°C (/s) –3.5 ± 2.4 –1.2 ± 2.3
CLT37°C (min) 491 ± 430 > 0.05 630 ± 502 > 0.05
CLT32°C (min) 479 ± 446 628 ± 549
The data shown are the mean and standard deviation of four  
separate assays.
*Statistically significantly different from that at 32°C at the  
p < 0.05 level.
Significant differences at different time points for MTH and NT  
between parameters at 37°C vs. 32oC: 1) the mean of a; 2) the  
mean of LY60.
Table 4. Summary of standard laboratory values from whole blood without using heparin.
Parameter Basal MTH NT
AT III [%] 81 (10) 68 (8)* 76 (9)§
Fibrinogen [g/L] 3.0 (0.8) 3.1 (0.9) 5.4 (1.2)‡§
PLT [10-3/µL] 192 (56) 151 (38)* 138 (50)‡
APTT [s] 28 (13) 34 (9)* 31 (6)‡
INR 1.2 (0.3) 1.2 (0.2) 1.1 (0.2)
DD [µg/L] 18316 (13865) 3253 (3538)* 1567 (1417)‡§
ACT [ms] 121 (21) 116 (14) 119 (14)
The data shown are the mean and standard deviation (SD).*p < 0.05 (MTH vs. Basal); ‡p < 0.05 (NT vs. Basal); §p < 0.05 (NT vs. MTH)
ACT — activated clotting time; APTT — activated partial thromboplastin time; AT III — antithrombin III; DD — D-dimer; INR — international  
normalized ratio; MTH — mild therapeutic hypothermia; NT — normothermia; PLT — platelets
Significant differences between time points MTH vs. Basal: (1) the mean of AT III; (2) the mean of PLT counts; (3) the mean of APTT;  
(4) the mean of DD.
Significant differences between time points NT vs. Basal: (1) the mean of fibrinogen; (2) the mean of PLT counts; (3) the mean of APTT;  
(4) the mean of DD.
Significant differences between time points NT vs. MTH: (1) the mean of AT III; (2) the mean of fibrinogen; (3) the mean of DD.
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pairment of hemostasis during MTH application 
was proved. Variables resulted during both analy-
ses were comparable [21, 25, 29]. The R variable, 
corresponding to clotting time in ROTEM®, is the 
value most influenced by activity of coagulation 
factors. In this study, R was not extended during 
MTH, compared to NT, under both in vivo and 
in vitro conditions. This agreed with previous 
observations but was inconsistent with others 
[10, 21, 30–32]. The first inconsistency could be 
explained by negligible temperature dependence of 
coagulation factors that form part of the extrinsic 
coagulation cascade. This step consists of two re-
actions: the coupling of factor VII/VIIa with tissue 
factor and the subsequent activation of factor X. 
Active cooling to 32°C did not influence activity and 
plasma levels of factor VII, which is the coagulation 
factor with the shortest half-life [32]. The second 
inconsistency, a significant R prolongation after 
induction of MTH, was observed in studies mainly 
involving surgical patients [32, 33] and could be 
a consequence of inhaled anaesthetics and propofol 
effects, which are believed to have an effect on 
hemostatic function [34]. Variables correspond-
ing to a, K, and MA in TEG are defined as a, clot 
formation time, and maximum clot firmness in 
ROTEM, respectively. Decreases in their values 
may reflect the impairment of the platelet count 
and activity as well as significantly lower fibrino-
gen levels during MTH compared to basal NT and 
NT after rewarming [30]. In this study, fibrinogen 
levels were significantly higher at NT compared 
to those under MTH and basal conditions. In the 
present observation, as fibrinogen levels have an 
impact on blood clot strength, stability, and velocity 
of formation, its levels corresponded with values 
of a-angle and MA, respectively. Such relation-
ships were observed in vivo (a-angle, MA) as 
well as in vitro (a-angle), which is consistent with 
previous observations [21, 30]. The most likely 
explanation for this finding is that elevated levels 
of fibrinogen in NT were related to acute phase 
reaction to ischemic-reperfusion injury caused 
by earlier cardiac arrest in OHCA survivors [11, 
35]. MTH had an impact on decreased platelet 
blood count, compared to basal NT which has been 
referred to in previous studies [21, 36]. In this 
study, the decrease remained within the normal 
range during MTH had no clinical impact on co-
agulation impairment. A tendency toward platelet 
count decrease during MTH may be explained 
as platelet margination and formation of platelet 
and platelet/leukocyte aggregates (which may 
depend on the level and duration of hypothermia) 
or by hepatic and splenic sequestration [37–39]. 
Another explanation of this phenomenon may be 
a cold-induced decrease in bone marrow function 
[40]. The persistent decrease in a platelet count, 
which was observed in the observed group after 
rewarming, may also be explained by periopera-
tive blood loss (during pPCI), which is consistent 
with previous studies involving invasively-treated 
patients [29]. TEG analysis of fibrinolysis dynamics 
was brought to a conclusion that one of the possible 
mechanisms leading to reduced clot solubility dur-
ing therapeutic hypothermia is a higher secretion 
of tissue plasminogen activator by endothelial 
cells and a slower conversion of plasminogen to 
plasmin. Similar findings have been previously 
observed in other studies [41, 42]. The dysfunction 
in coagulation and fibrinolysis systems observed 
in vitro may be clinically relevant as a tendency 
toward bleeding complications via impaired clot 
formation. However, the present study group con-
sisted of a relatively small number of patients to 
thoroughly study this relationship; the statistical 
power of this group was insufficient to bring us to 
such clinical conclusions. As a standard feature, in 
most TEG studies blood tests were performed at 
37°C, regardless of patient body temperature. This 
study examined whether the sample temperature 
had an impact on coagulation impairment during 
the TEG evaluation, similar studies has been per-
formed for different patient groups with samples 
collected during MTH [27, 31, 35]. The MTH ef-
fects on coagulation tests from both in vivo (patient 
treatment) and in in vitro conditions (TEG) were 
analyzed. The in vitro results were different with 
respect to in vivo data; the delayed (prolonged) 
initiation of clot formation (lower a) and impaired 
tendency to clot lysis (lower LY60) were observed 
when TEG was performed at 37°C, while there 
were no effects on the MA, K and CI. These last 
findings were consistent with those previously 
obtained in other in vitro hypothermic studies [20, 
28, 36, 43]. The present approach to analyze blood 
samples collected from patients during MTH at 
32°C and 37°C allowed a more accurate assessment 
of cooling-induced coagulation impairment. The 
finding that TEG results may be affected by the in 
vitro temperatures have already been confirmed in 
some studies [15, 28, 31, 43], while in other studies 
it was considered insignificant [19, 44]. However, 
in the largest randomized clinical trial conducted to 
date by Nielsen et al. [45], it was shown that there 
were no differences in risk of death and neurologi-
cal outcome between group with 33°C (MTH) vs. 
36°C of targeted temperature management (TTM) 
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This takes into consideration new ILCOR guide-
lines which recommend both therapies — MTH or 
targeted temperature management are nowadays 
the standard procedures in OHCA patients. In 
this prospective study,  previous findings were 
confirmed that TEG is an effective tool for the 
effect of MTH on coagulation disorders both in 
vivo and in vitro [26]. Blood samples collected at 
regular intervals after OHCA have allowed a reli-
able comparison of blood coagulation parameters 
during MTH and then in the rewarming phase. In 
conclusion, based on TEG evaluation, hypothermia 
appears to impair coagulation and platelet function. 
Limitations of the study
The limitation of the TEG method is low repro-
ducibility, when performed by unqualified personnel. 
In this context, routine use of TEG could help prevent 
the occurrence of severe bleeding or thromboembolic 
complications, thus increasing the survival chances of 
patients with OHCA undergoing pPCI. Some limita-
tions have to be considered. The first limitation is the 
low number of patients admitted to this study (21), 
which did not allow correlation of TEG results with 
clinical events. A second limitation was the lack of a 
control group; the current guidelines recommend the 
use of MTH in all patients with OHCA, and ethical 
standards will most likely prevent further randomized 
trials that withhold hypothermia in order to establish 
a control group. Although validation of results using 
a randomized controlled approach seems preferable, 
according to the design of this study, patients actually 
served as their own controls. Finally, TEG variables 
were not measured before hypothermia induction. 
Conclusions
Thromboelastography appears to be a use-
ful method for evaluation of coagulation system 
dysfunction in OHCA survivors undergoing thera-
peutic hypothermia. Coagulation impairment in 
hypothermia was associated with a reduced rate of 
clot formation, increased weakness of clot strength, 
and disturbances of fibrinolysis and most likely 
results from reduced fibrinogen levels and platelet 
activity. Blood sample analyses performed at 32°C 
during MTH, instead of the standard 37°C, seems 
to enhance the accuracy in evaluation of coagula-
tion impairment in hypothermia.
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